​

BioXcel Therapeutics (BTAI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BTAI Stock Forecast

BioXcel Therapeutics (BTAI) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $25.00 and a low of $1.00. This represents a 559.34% increase from the last price of $1.82.

- $5 $10 $15 $20 $25 High: $25 Avg: $12 Low: $1 Last Closed Price: $1.82

BTAI Stock Rating

BioXcel Therapeutics stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (53.85%), 6 Hold (46.15%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 6 7 0 Strong Sell Sell Hold Buy Strong Buy

BTAI Price Target Upside V Benchmarks

TypeNameUpside
StockBioXcel Therapeutics559.34%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$1.00
Last Closing Price$1.82$1.82$1.82
Upside/Downside---45.05%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25111-14
Mar, 25111-14
Feb, 25111-14
Jan, 25121-15
Dec, 24122--5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 23, 2024Graig SuvannavejhMizuho Securities$1.00$0.5969.49%-45.05%
Apr 15, 2024Raghuram SelvarajuH.C. Wainwright$10.00$2.90244.83%449.45%
Aug 15, 2023Graig SuvannavejhMizuho Securities$4.00$3.980.50%119.78%
Jan 03, 2023H.C. Wainwright$73.00$21.48239.85%3910.99%
Nov 11, 2022Guggenheim$25.00$14.8268.69%1273.63%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 21, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024H.C. WainwrightBuyBuyhold
Apr 15, 2024H.C. WainwrightBuyBuyhold
Aug 15, 2023Wells FargoBuyBuyhold
May 26, 2023Goldman SachsNeutralNeutralhold
Mar 21, 2023Piper SandlerBuyBuyhold
Mar 10, 2023OppenheimerOutperforminitialise
Dec 01, 2022Goldman SachsNeutralupgrade
Nov 11, 2022GuggenheimBuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-20 $-15 $-10 $-5 $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-6.13$-6.15$-23.51----
Avg Forecast$-5.20$-5.90$-1.60$-1.28$-0.76$-0.36$-0.29
High Forecast$-3.16$-5.59$-1.39$-1.24$-0.46$-0.15$-0.15
Low Forecast$-8.42$-6.35$-1.80$-1.32$-1.11$-0.57$-0.54
Surprise %17.88%4.24%1369.38%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$375.00K$1.38M$2.27M----
Avg Forecast$1.18M$1.71M$2.27M$6.02M$11.91M$60.00M$106.55M
High Forecast$1.74M$2.37M$3.82M$10.15M$11.91M$101.22M$179.75M
Low Forecast$823.91K$1.19M$1.41M$3.74M$11.91M$37.33M$66.29M
Surprise %-68.25%-19.53%-0.01%----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-171.85M$-179.05M$-59.60M----
Avg Forecast$-151.43M$-179.05M$-46.51M$-37.30M$-22.82M$-10.49M$-8.30M
High Forecast$-91.92M$-162.72M$-40.57M$-36.05M$-13.41M$-4.37M$-4.22M
Low Forecast$-245.36M$-185.05M$-52.45M$-38.55M$-32.23M$-16.60M$-15.72M
Surprise %13.48%-28.14%----

BTAI Forecast FAQ

Is BioXcel Therapeutics stock a buy?

BioXcel Therapeutics stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioXcel Therapeutics is a favorable investment for most analysts.

What is BioXcel Therapeutics's price target?

BioXcel Therapeutics's price target, set by 13 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $1 at the low end to $25 at the high end, suggesting a potential 559.34% change from the previous closing price of $1.82.

How does BioXcel Therapeutics stock forecast compare to its benchmarks?

BioXcel Therapeutics's stock forecast shows a 559.34% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for BioXcel Therapeutics over the past three months?

  • April 2025: 25.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 25.00% Strong Sell.
  • March 2025: 25.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 25.00% Strong Sell.
  • February 2025: 25.00% Strong Buy, 25.00% Buy, 25.00% Hold, 0% Sell, 25.00% Strong Sell.

What is BioXcel Therapeutics’s EPS forecast?

BioXcel Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.28, marking a -94.56% decrease from the reported $-23.51 in 2024. Estimates for the following years are $-0.76 in 2026, $-0.36 in 2027, and $-0.29 in 2028.

What is BioXcel Therapeutics’s revenue forecast?

BioXcel Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $6.02M, reflecting a 165.53% increase from the reported $2.27M in 2024. The forecast for 2026 is $11.91M, followed by $60M for 2027, and $106.55M for 2028.

What is BioXcel Therapeutics’s net income forecast?

BioXcel Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-37.303M, representing a -37.41% decrease from the reported $-59.599M in 2024. Projections indicate $-22.821M in 2026, $-10.486M in 2027, and $-8.302M in 2028.